Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) has announced that it will report its second quarter 2024 financial results after market close on Tuesday, August 6, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) has announced that it will report its second quarter 2024 financial results after market close on Tuesday, August 6, 2024. The company's senior management will host a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and provide a business update. Participants can join the call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The call and accompanying slides will also be webcast live from the Investor Relations section of Rigel's website at www.rigel.com, where it will be archived for 90 days after the call.
Details
News Market Reaction – RIGL
The recorded move for RIGL in the trading session of this news was +0.28%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
Phone: 212.600.1902
Email: david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2024-financial-results-and-business-update-302209261.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.